Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 7, 2007, Pages 594-600

  Mawatari, Eiichiro ^a   Hongo, Minoru ^b   Sakai, Akio ^a   Terasawa, Fumiko ^b   Takahashi, Masafumi ^c   Yazaki, Yoshikazu ^a   Kinoshita, Osamu ^a   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium channel blocker; Endothelial dysfunction; Nitric oxide; Pulmonary circulation

Indexed keywords

AMLODIPINE; CYCLINE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; MESSENGER RNA; MONOCROTALINE; PADGEM PROTEIN; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RANDOMIZATION; RAT; SURVIVAL RATE; UPREGULATION;

AMLODIPINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MATRIX METALLOPROTEINASE 2; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; P-SELECTIN; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 34250751672     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04618.x     Document Type: Article

References (45)

1. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research 'Work in progress'. Circulation 2000 102 : 2781 91.
2. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis. 2002 45 : 173 202.
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N. Engl. J. Med. 2004 351 : 1655 65.
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004 351 : 1425 36.
5. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995 333 : 214 21.
6. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004 109 : 159 65.
7. Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit Care Med. 1999 159 : 1925 32.
8. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993 328 : 1732 9.
9. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog. Cardiovasc. Dis. 2002 45 : 213 24.
10. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002 165 : 1209 16.
11. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 2005 143 : 282 92.
12. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998 97 : 576 80.
13. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004 70 : 39 45.
14. Stepien O, Gogusev J, Zhu DL et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J. Cardiovasc. Pharmacol. 1998 31 : 786 93.
15. Ikeda U, Hojo Y, Ueno S, Arakawa H, Shimada K. Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J. Cardiovasc. Pharmacol. 2000 35 : 887 90.
16. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000 12 : 294 7.
17. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous anti-oxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol. 1997 30 : 569 75.
18. Mason RP, Walter MF, Trumbore MW, Olmstead Jr. EG, Mason PE. Membrane anti-oxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J. Mol. Cell. Cardiol. 1999 31 : 275 81.
19. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 102 : 1503 10.
20. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004 292 : 2217 25.
21. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005 366 : 895 906.
22. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis 2002 165 : 191 9.
23. Franz IW, Van Der Meyden J, Schaupp S, Tönnesmann U. The effect of amlodipine on exercise-induced pulmonary hypertension and right heart function in patients with chronic obstructive pulmonary disease. Z. Kardiol. 2002 91 : 833 9.
24. Takahashi T, Kanda T, Imai S, Suzuki T, Kobayashi I, Nagai R. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Res. Commun. Mol. Pathol. Pharmacol. 1996 91 : 17 32.
25. Hironaka E, Hongo M, Sakai A et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc. Res. 2003 60 : 692 9.
26. Hongo M, Mawatari E, Sakai A et al. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J. Cardiovasc. Pharmacol. 2005 46 : 452 8.
27. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography. Detection of picogram quantities of gelatinases. Anal. Biochem. 1994 218 : 325 9.
28. Kanwar YS, Ota K, Yang Q et al. Role of membrane-type matrix metalloproteinase 1 (MT-1-MMP), MMP-2 and its inhibitor in nephrogenesis. Am. J. Physiol. 1999 277 : F934 47.
29. Mattson DL, Wu F. Nitric oxide synthase activity and isoforms in rat renal vasculature. Hypertension 2000 35 : 337 41.
30. Suzuki F, Hashikura Y, Ise H et al. MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischaemia-reperfusion injury in rats. Transpl. Int. 2005 18 : 844 53.
31. Gazin V, Kerdine S, Grillon G, Pallardy M, Raoul H. Uranium induces TNF alpha secretion and MAPK activation in a rat alveolar macrophage cell line. Toxicol. Appl. Pharmacol. 2004 194 : 49 59.
32. Ghofrani HA, Pepke-Zaba J, Barbera JA et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004 43 (Suppl. S68 72.
33. Tabrizchi R. Amlodipine and endothelial nitric oxide synthase activity. Cardiovasc. Res. 2003 59 : 807 9.
34. Salameh A, Schomecker G, Breitkopf K, Dhein S, Klaus W. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br. J. Pharmacol. 118 : 1996 1899 904.
35. Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. 2002 39 : 208 14.
36. Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc. Res. 2003 59 : 844 53.
37. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003 111 : 1201 9.
38. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 2000 6 : 698 702.
39. Nishimura T, Vaszar LT, Faul JL et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003 108 : 1640 5.
40. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004 94 : 385 93.
41. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 2005 115 : 2811 21.
42. McMurtry MS, Archer SL, Altieri DC et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 2005 115 : 1479 91.
43. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells. Efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. 2005 96 : 442 50.
44. Kao PN. Simvastatin treatment of pulmonary hypertension: An observational case series. Chest 2005 127 : 1446 52.
45. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 111 : 3105 11.